Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2027
Summary There is a high level of unmet need that is beginning to be addressed by pharmaceutical companies and this in turn is driving the modest growth of the global Plaque psoriasis market. Global Plaque psoriasis market is expected to grow from $16.2bn in 2017 to $24.2bn in 2027 across the seven major markets (7MM - The US, France, Germany, Italy, Spain, the UK and Japan) at a compound annual growth rate of 4.1%.
Psoriasis is an incurable, chronic and systemic inflammatory skin disorder with a prevalence of 2-3% worldwide.The exact cause of psoriasis is unknown, although it is believed that environmental factors, skin barrier disruptions, and immune dysfunctions are key components that induce the development of psoriasis.
The most common form of psoriasis is plaque psoriasis (psoriasis vulgaris), which is the focus of this report.
The Plaque psoriasis market is currently very dynamic, with novel pipeline therapies being developed. As well as the recent launch of UCB’s Cimzia and Sun Pharma’s Ilumya, will challenge the current tumor necrosis factor (TNF), IL-17 and IL-23 inhibitors, and small molecule compounds.
However, there are still a number of unmet clinical needs in the Plaque psoriasis market, especially relating to the lack of oral therapies and safe topical therapies.These needs have been emphasized by various key opinion leaders (KOLs) interviewed.
Furthermore, KOLs have highlighted that there is a lack of safe and efficacious treatment alternatives for pregnant and breastfeeding women.
Blockbuster drugs such as Amgen’s Enbrel (etanercept), Janssen’s Remicade (infliximab) and AbbVie’s Humira (adalimumab) have dominated the Plaque psoriasis market for over 10 years.Nevertheless, this is set to change as there has been increasing development of new therapeutics, particularly within the IL-17 and IL-23 classes.
Furthermore, companies are racing to bring their biosimilars to the market. As a result, it will be difficult for any one product to become and remain a market leader in a heavily competitive market.
There are many companies that are striving to enter the Plaque psoriasis market and many of the drugs target moderate and severe Plaque psoriasis patients.However, the most neglected segment is the mild severity.
There are limited treatment options other than topical and small molecule therapeutics and this is a high unmet need.
The latest report "Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2027", provides key metrics for Plaque Psoriasis (Epidemiology, Market Size, Product Pipeline, Key Events, Competitive Analysis) in the seven major pharmaceutical markets (7MM) covered in this report-the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan-during the forecast period from 2017-2027.
Key Questions Answered - How will the Psoriasis market landscape in the 7MM (US, France, Germany, Italy, Spain, UK and Japan) change from 2017-2027? - What are the most promising late-stage pipeline drugs in Plaque Psoriasis? - How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another and against existing treatment options? - What are the greatest unmet needs in Plaque Psoriasis? Will the pipeline drugs fulfil these needs of the market? - What are the largest opportunities in the Plaque Psoriasis landscape?
Scope - Overview of Plaque psoriasis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies. - Topline Plaque psoriasis market revenue from 2017-2027. ACOT and major pipeline product sales in this forecast period are included. - Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting Plaque psoriasis therapeutics sales in the 7MM. - Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products. - Analysis of the current and future market competition in the global Plaque psoriasis therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy The report will enable you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Plaque psoriasis therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Plaque psoriasis therapeutics market in the future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Our reports have been used by over 10K customers, including:
Leptin Receptor - Pipeline Review, H2 2019 Summary Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) pipeline Target constitutes close to 7 molecules. The latest report Leptin Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Leptin Receptor (HuB219 or OB Receptor...
Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2019 Summary Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) pipeline Target constitutes close to 25 molecules. Out of which approximately...
Integrin Alpha 4 - Pipeline Review, H2 2019 Summary Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) pipeline Target constitutes close to 16 molecules. The latest report Integrin Alpha 4 - Pipeline Review, H2 2019, outlays comprehensive information on the...
Integrin Beta 7 - Pipeline Review, H2 2019 Summary Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium...
Alpha Synuclein - Pipeline Review, H2 2019 Summary Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it...
219 pages •
By Asia Market Information & Development Company
• Oct 2019
China’s demand for Monoclonal Antibody has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...